Pharsight

1. List of Juxtapid drug patents

Application	Filing Date	Opposition Party	Legal Status
EP05724887A	2013-08-21	Stein, Evan MD PhD	Patent maintained as amended

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
US7932268	August, 2015	FWD Entered	The Trustees of the University of Pennsylvania)	Coalition for Affordable Drugs VIII
US8618135	August, 2015	FWD Entered	The Trustees of the University of Pennsylvania	COALITION FOR AFFORDABLE DRUGS VIII, LLC

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10555938	AMRYT	Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects	Mar, 2025 (1 year, 11 months from now)
US8618135	AMRYT	Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects	Mar, 2025 (1 year, 11 months from now)
US9265758	AMRYT	Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects	Mar, 2025 (1 year, 11 months from now)
US9364470	AMRYT	Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects	Mar, 2025 (1 year, 11 months from now)
US9433617	AMRYT	Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects	Mar, 2025 (1 year, 11 months from now)
US9861622	AMRYT	Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects	Mar, 2025 (1 year, 11 months from now)
US10016404	AMRYT	Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects	Mar, 2025 (1 year, 11 months from now)
US7932268	AMRYT	Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects	Aug, 2027 (4 years from now)

Market Authorisation Date: 21 December, 2012

Treatment: A dosing regimen for the treatment of hypercholesterolemia and hyperlipidemia in patients with homozygous familial hypercholesterolemia using at least three step-wise increasing doses; A dosing regimen for the treatment of hypercholesterolemia and hyperlipidemia in patients with homozygous familial hypercholesterolemia using at least three step-wise increasing doses

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 5MG BASE	CAPSULE;ORAL	Prescription
EQ 10MG BASE	CAPSULE;ORAL	Prescription
EQ 20MG BASE	CAPSULE;ORAL	Prescription
EQ 30MG BASE	CAPSULE;ORAL	Prescription
EQ 40MG BASE	CAPSULE;ORAL	Discontinued
EQ 60MG BASE	CAPSULE;ORAL	Discontinued